Cargando…
Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
BACKGROUND: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. METHODS: We compared two groups of patients with a fairly similar prognosis either receiving Aflibercept or R...
Autores principales: | Böhni, Sophie C., Bittner, Mario, Howell, Jeremy P., Bachmann, Lucas M., Faes, Livia, Schmid, Martin K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546020/ https://www.ncbi.nlm.nih.gov/pubmed/26289356 http://dx.doi.org/10.1186/s12886-015-0101-4 |
Ejemplares similares
-
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010) -
Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
por: Strong, Stacey A., et al.
Publicado: (2016) -
Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data
por: Reich, Oliver, et al.
Publicado: (2015) -
Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration
por: Reis, Gustavo MSM, et al.
Publicado: (2017) -
Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
por: Zhao, Xuli, et al.
Publicado: (2022)